RxDoctor Payments Data

James Krablin, MD

Internal Medicine · Lexington, OKNPI 1679509657

Payments from drug & device makers

$151in general payments, 2019–2025

Across 11 payments — averaging $13.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$35
  • SK Life Science, Inc.$24
  • Otsuka America Pharmaceutical, Inc.$21
  • Sumitomo Pharma America, Inc.$21
  • Acadia Pharmaceuticals Inc$19
  • Dexcom, Inc.$17
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$151 in reported general payments places this provider in the 40th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$1,325,625
Medicare patients
1,905
Services billed
15,548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,599$1,061,898
AustedoDeutetrabenazine79$450,478
Invega SustennaPaliperidone Palmitate86$282,726
VraylarCariprazine Hcl340$256,091
NuplazidPimavanserin Tartrate61$191,418
JardianceEmpagliflozin427$180,719
XareltoRivaroxaban380$162,771
IngrezzaValbenazine Tosylate26$142,780
JanuviaSitagliptin Phosphate422$136,248
RexultiBrexpiprazole121$115,376
MyrbetriqMirabegron341$113,411
NuedextaDextromethorphan Hbr/Quinidine156$112,880
Trelegy ElliptaFluticasone/Umeclidin/Vilanter172$112,294
OzempicSemaglutide99$102,689
TrintellixVortioxetine Hydrobromide340$88,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$19$191,41861 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$21$157,390135 claims
Sumitomo Pharma America, Inc.Gemtesa$21$68,717248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Lexington

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →